Regorafenib (BAY 73-4506)

Catalog No.S1178 Synonyms: Fluoro-Sorafenib

Regorafenib (BAY 73-4506) Chemical Structure

Molecular Weight(MW): 482.82

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 470 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.
Targets
RET [1]
(Cell-free assay)
Raf-1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
Kit [1]
(Cell-free assay)
VEGFR1 [1]
(Cell-free assay)
1.5 nM 2.5 nM 4.2 nM 7 nM 13 nM
In vitro

Regorafenib strongly prevents VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with IC50 of 3 nM. In HAoSMCs, regorafenib suppress PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib also inhibits FGFR signaling in MCF-7 breast cancer (BC) cells stimulated with FGF10. Regorafenib very potently inhibited the mutant receptors KITK642E and RETC634W, with IC50 of approximately 20 nM and 10 nM, respectively. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC50 of approximately 3 nM. Regorafenib prevents the proliferation of FGF2-stimulated HUVECs and of PDGF-BB-stimulated HAoSMCs with IC50 of 127 nM and 146 nM, respectively. [1] Regorafenib targets both tumor cell proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases (VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (Raf and p38MAPK). [2] Regorafenib suppresses growth of human Hep3B, PLC/PRF/5 and HepG2 cells in a concentration- and time-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Hep3B NWPmZoVSSXCxcITvd4l{KEG|c3H5 MW[x5qCUPcLizszN MmrvOFghcA>? MoDCbY5pcWKrdIOgZ4VtdCCpcn;3eIg> NFrXeHQzPjN{OU[wPC=>
PLC/PRF/5  NVzISVZlSXCxcITvd4l{KEG|c3H5 NFXpTWcy6oDVNdMg{txO MmfGOFghcA>? NFPpU4VqdmirYnn0d{Bk\WyuIHfyc5d1cA>? MUGyOlMzQTZyOB?=
HepG2  M335bmFxd3C2b4Ppd{BCe3OjeR?= M13l[|HjiJN3wrFOwG0> NE\ZR5I1QCCq MlfsbY5pcWKrdIOgZ4VtdCCpcn;3eIg> M4G3XFI3OzJ7NkC4
HEK293 NIPSPZJHfW6ldHnvckBCe3OjeR?= NGH0SngxNjYkgJpOwG0> MlLtNk81NzZiaB?= NHrnfnlz\WS3Y3XzJGdTWDd6IHX4dJJme3Orb36= NGe5dnIzPTh3OECzNi=>
GEO M2nYe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmwMlAyNTJyIN88US=> NHnlN2U6PiCq NIrmTI9FVVOR MYHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MlX2NlU5Ozh|OUG=
SW48 M2DSSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHGOW8xNjBzLUKwJO69VQ>? MWG5OkBp NH:5WWVFVVOR MULpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M3nqUVI2QDN6M{mx
HT29 Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOwMlAyNTJyIN88US=> MofSPVYhcA>? M37De2ROW09? MWHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NYjzbmZ7OjV6M{izPVE>
SW480 NWr5VWJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jQWVAvODFvMkCg{txO NVfvOVB2QTZiaB?= NGnvOpVFVVOR MXnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MX6yOVg{QDN7MR?=
SW620 Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\odFAvODFvMkCg{txO M2HR[lk3KGh? MlLVSG1UVw>? NWezXoQycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVSyOVg{QDN7MR?=
HCT116 M2i4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmwMlAyNTJyIN88US=> NGDVSZU6PiCq MmDtSG1UVw>? NYXSXZV2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MkK3NlU5Ozh|OUG=
LOVO NHLTbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDTNE4xOS1{MDFOwG0> M4PNXFk3KGh? Mn:2SG1UVw>? M3PYfYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXixXnVCOjV6M{izPVE>
HCT150 NHvROoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXDSYpQOC5yMT2yNEDPxE1? M4X1R|k3KGh? MXfEUXNQ MU\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MX2yOVg{QDN7MR?=
SW48-CR NF\FUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;6Z4YxNjBzLUKwJO69VQ>? MWK5OkBp NUXXUolTTE2VTx?= NILSS5pqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1m2ZVI2QDN6M{mx
GEO-CR M13iXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX6wMlAyNTJyIN88US=> NVLIWVNHQTZiaB?= NFLnW25FVVOR NVi3SJRucW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYOyOVg{QDN7MR?=
KB-31 Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTVwNdMxNE4{KG6P MVSyOVc2OzN4MR?=
KB-G2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTlwMdMxNE4yKG6P NXHYcFcxOjV5NUOzOlE>
LLC-PK1 NVrsdJJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPkeotlUUN3ME20Nk4xyrF|LkKgcm0> MmGyNlU4PTN|NkG=
LLC-PK1/MRP2 NGDtNFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXy3ZXRoUUN3ME24Nk41yrF{Lkegcm0> NUmze4MzOjV5NUOzOlE>
HEK293 M3;6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFzLkFCtVEvOiCwTR?= NFzzV|IzPTd3M{O2NS=>
HEK293/OATP1B1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HMXmlEPTB;Nj6yxtExNjNibl2= NF7vWGszPTd3M{O2NS=>
HROC18 MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7VTWM2OD1zLkOg{txO M4f4XFI2OzB7OUG0
HROC24 M{HkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfBVY5KSzVyPUSuOkDPxE1? M{LFT|I2OzB7OUG0
HROC43 NVHRVphNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfrdGNqUUN3ME21MlMh|ryP NFqzS24zPTNyOUmxOC=>
HROC46 Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXQW3R3UUN3ME2yMlQh|ryP M3fjSVI2OzB7OUG0
RJ345 MWDGeY5kfGmxbjDBd5NigQ>? MmD3NE42NzVizszN MUSyOEBp NFX1O4JFVVOR M{XFWYlvcGmkaYTzJJRp\SClZXzsJI1q\3KjdHnvci=> M4PVTFI2OjV|OUm0
RJ348 MlHCSpVv[3Srb36gRZN{[Xl? MmK4NE42NzVizszN MWmyOEBp M17xcmROW09? NWHSdFlscW6qaXLpeJMhfGinIHPlcIwhdWmpcnH0bY9v MUmyOVI2Ozl7NB?=
MCF-7 NIj1WZZHfW6ldHnvckBCe3OjeR?= MlfwNE42NzVizszN M1GwWFI1KGh? MYjEUXNQ NVHXPIRMcW6qaXLpeJMhfGinIHPlcIwhdWmpcnH0bY9v NGOwTI8zPTJ3M{m5OC=>
MDA-MB-231 M3y5OGZ2dmO2aX;uJGF{e2G7 MUewMlUwPSEQvF2= M1fqcFI1KGh? MU\EUXNQ M{nSW4lvcGmkaYTzJJRp\SClZXzsJI1q\3KjdHnvci=> NV7DdIVqOjV{NUO5PVQ>
HT15 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETmW4kyNTJyIN88US=> M3X6U|Q5KGh? MmPKbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MoTvNlUxPzFyMUi=
DLD1 Ml3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\GbVEuOjBizszN NYexS3NrPDhiaB?= NXHHe4tKcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVrYOIRqOjVyN{GwNVg>
HT-29 M3n0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHUZZQyNTJyIN88US=> M3XjbVQ5KGh? NV;lNnlScW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NGftXIszPTB5MUCxPC=>
Hct-116 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LwVVEuOjBizszN NX7jemJvPDhiaB?= M3nUNIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MoS2NlUxPzFyMUi=
HT15 M2jVZWFxd3C2b4Ppd{BCe3OjeR?= NHzjV5EyNTFyIN88US=> M17jUlQ5KGh? NF62THZqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NEDpfZIzPTB5MUCxPC=>
DLD1 MlvXRZBweHSxc3nzJGF{e2G7 M4jtOFEuOTBizszN MYW0PEBp NFrPbVhqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M4fGW|I2ODdzMEG4
HT-29 M4rtcGFxd3C2b4Ppd{BCe3OjeR?= M3X4flEuOTBizszN MYG0PEBp MnHsbY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M4XSWFI2ODdzMEG4
Hct-116 MnrHRZBweHSxc3nzJGF{e2G7 MVWxMVExKM7:TR?= NHXJR5Q1QCCq NGHYOZlqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFXRWIwzPTB5MUCxPC=>
GBM5 NHe3fXRCeG:ydH;zbZMhSXO|YYm= MV2wMlXjiJNzLkFihKnPxE1? NGXpdoszPCCq NFL0R3lFVVOR MoXKbY51\XKjY4TzJJdqfGhibHHwZZRqdmmkIITvJIlv\HWlZTDj[YxtKGSnYYTo M2HpRVI1QTFzMkG1
GBM6 MoP4RZBweHSxc3nzJGF{e2G7 NEm1[48xNjYkgKOxMlDjiIoQvF2= Mn;1NlQhcA>? MnXJSG1UVw>? NU\ZTIxwcW62ZYLhZ5R{KHerdHigcIFx[XSrbnniJJRwKGmwZIXj[UBk\WyuIHTlZZRp MXKyOFkyOTJzNR?=
GBM12 NVS0fGJnSXCxcITvd4l{KEG|c3H5 MX:wMlXjiJNzLkFihKnPxE1? NEDG[ZczPCCq NHv2e2lFVVOR MnHlbY51\XKjY4TzJJdqfGhibHHwZZRqdmmkIITvJIlv\HWlZTDj[YxtKGSnYYTo MX6yOFkyOTJzNR?=
GBM14  MUjBdI9xfG:|aYOgRZN{[Xl? NETSTGwxNjYkgKOxMlDjiIoQvF2= NXrndZE{OjRiaB?= MVjEUXNQ NVi4Z|lrcW62ZYLhZ5R{KHerdHigcIFx[XSrbnniJJRwKGmwZIXj[UBk\WyuIHTlZZRp MVuyOFkyOTJzNR?=
Hep3B M1;P[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXex5qCUOi53wrFOwG0> NVLDdoNIOjRxNEivO|IhcA>? NGjWOIxqdmirYnn0d{Bk\WyuIHfyc5d1cA>? NHvVPIIzPDh6NUi5NC=>
PLC/PRF/5  MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfvc5Qy6oDVMj61xsDPxE1? NWnkZ2o5OjRxNEivO|IhcA>? NYDwd21ncW6qaXLpeJMh[2WubDDndo94fGh? MX6yOFg5PTh7MB?=
HepG2  M3vvNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LEclHjiJN{LkZCpO69VQ>? NInTSo0zPC92OD:3NkBp MkPRbY5pcWKrdIOgZ4VtdCCpcn;3eIg> MkPDNlQ5QDV6OUC=
HCT116  MV;GeY5kfGmxbjDBd5NigQ>? NHXnVG8yOC9{MD:0NEDPxE1? MXuyOEBp M{P3ZYlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDtVm5CKGW6cILld5Nqd25iaX6gZUBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NVP6[2k{OjR5NkO2NVE>
Lim2405 MWLGeY5kfGmxbjDBd5NigQ>? MlHQOFAh|ryP NIPMTVAzPCCq NInQSlJqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? MVqyOFc3OzZzMR?=
LoVo M2jPSGZ2dmO2aX;uJGF{e2G7 NH7K[Yk1OCEQvF2= NX7BNZV3OjRiaB?= MkmxbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ NIPhfXgzPDd4M{[xNS=>
Lim1215 M3X1OWZ2dmO2aX;uJGF{e2G7 NF\X[FA1OCEQvF2= MW[yOEBp NHniTlZqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? MoHyNlQ4PjN4MUG=
SW48 M{PPOGZ2dmO2aX;uJGF{e2G7 NYPOenVDPDBizszN NGjkOVAzPCCq Mlm3bY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ NEm4TnozPDd4M{[xNS=>
RKO  M2HtdmZ2dmO2aX;uJGF{e2G7 MmnwOFAh|ryP MUeyOEBp Mn7tbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ NEDLUHgzPDd4M{[xNS=>
SW837 MnraSpVv[3Srb36gRZN{[Xl? NHzHZWI1OCEQvF2= M1LSSVI1KGh? MkLmbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ NUn5SIx{OjR5NkO2NVE>
SW1463 M2HFN2Z2dmO2aX;uJGF{e2G7 MmnQOFAh|ryP M4e1Z|I1KGh? M4LkXolv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? M3TuNlI1PzZ|NkGx
SW480 MVXGeY5kfGmxbjDBd5NigQ>? NE\ZN|A1OCEQvF2= NVPSRmlEOjRiaB?= NEnVWHVqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? M3P0fVI1PzZ|NkGx
Vaco432 Mne4SpVv[3Srb36gRZN{[Xl? Ml71OFAh|ryP MmLUNlQhcA>? NIK2TVVqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? MkfXNlQ4PjN4MUG=
Vaco400 NEHWPWVHfW6ldHnvckBCe3OjeR?= MYO0NEDPxE1? MmnnNlQhcA>? MlXKbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ MWSyOFc3OzZzMR?=
DLD1 MkflSpVv[3Srb36gRZN{[Xl? M1rlWVQxKM7:TR?= NEXo[mczPCCq M4\sdIlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? M1PJWlI1PzZ|NkGx
HT29  M2D1eGZ2dmO2aX;uJGF{e2G7 NYDUTVVzPDBizszN NVvwb|R5OjRiaB?= NYq0VYs6cW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| NU\ne|BxOjR5NkO2NVE>
PLC/PRF/5  M17kbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzmNgKBmzYEtV2= NXO1VIlYOjRxNEivO|IhcA>? MnnYbY5pcWKrdIOgZ4VtdCCpcn;3eIg> NV\wUIVrOjNzNkmxOFg>
HepG2 MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWqx5qCUPcL3TR?= MmfVNlQwPDhxN{KgbC=> NEXBV2NqdmirYnn0d{Bk\WyuIHfyc5d1cA>? NHfjXGczOzF4OUG0PC=>
Hep3B  M4eyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nDPFHjiJN3wsXN NH\0[lAzPC92OD:3NkBp NEnYSm1qdmirYnn0d{Bk\WyuIHfyc5d1cA>? NFTYbZQzOzF4OUG0PC=>

... Click to View More Cell Line Experimental Data

In vivo Regorafenib reveals potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages in breast MDA-MB-231 and renal 786-O carcinoma models. Regorafenib prevents not only the growth of syngeneic primary 4T1 breast tumors growing orthotopically in the fat pad, but also suppresses the formation of tumor metastasis in the lung. [1]

Protocol

Kinase Assay:[1]
+ Expand

Kinase assays:

In vitro assays using recombinant VEGFR2 (murine aa785–aa1367), VEGFR3 (murine aa818–aa1363), PDGFRβ (aa561–aa1106), Raf-1 (aa305–aa648) and BRafV600E (aa409–aa765) kinase domains are performed. Initial in vitro kinase inhibition profiling is performed at a fixed 1 μM Regorafenib concentration. Inhibitory concentration of 50% (IC50) values are determined from selected responding kinases, e.g., VEGFR1 and RET. TIE2 kinase inhibition is measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate.
Cell Research:[1]
+ Expand
  • Cell lines: GIST 882 and TT cells
  • Concentrations: 5 nM-10 μM
  • Incubation Time: 96 hours
  • Method: For proliferation assays, GIST 882 and TT cells are grown in RPMI medium containing L-glutamine, and MDA-MB-231, HepG2 and A375 cells in DMEM always containing 10% hiFBS. Cells are trypsinized, plated at 5×104 cells/well in 96-well plates in complete media containing 10% FBS and grown overnight at 37 °C. The next day, vehicle or Regorafenib serially diluted in complete growth media to between 10 μM and 5 nM final concentrations, and 0.2% DMSO, is added and incubation is continued for 96 hours. Cell proliferation is quantified.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female athymic NCr nu/nu mice with Colo-205, MDA-MB-231 or 786-O
  • Formulation: PEG400/125 mM aqueous methanesulfonic acid (80/20) or polypropylene glycol/PEG400/Pluronic F68 (42.5/42.5/15 + 20% Aqua)
  • Dosages: 3 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 97 mg/mL (200.9 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 482.82
Formula

C21H15ClF4N4O3

CAS No. 755037-03-7
Storage powder
in solvent
Synonyms Fluoro-Sorafenib

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02795156 Recruiting Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer September 28, 2016 Phase 2
NCT03042689 Not yet recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Bayer January 2017 Phase 1
NCT02910843 Not yet recruiting Rectal Cancer Swiss Group for Clinical Cancer Research December 2016 Phase 1
NCT02940223 Not yet recruiting Malignant Neoplasms of Independent (Primary) Multiple Sites|Metastatic Colorectal Cancer M.D. Anderson Cancer Center|Bayer December 2016 Phase 2
NCT02955940 Enrolling by invitation Pancreatic Cancer|Colorectal Cancer|Breastcancer|Lung Cancer Non-Small Cell Incyte Corporation November 2016 Phase 2
NCT02889328 Recruiting Gastrointestinal Stromal Tumors (GISTs) Asan Medical Center September 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) supplier | purchase Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) cost | Regorafenib (BAY 73-4506) manufacturer | order Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID